Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for deve... Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. Mehr anzeigen
– Treatment with ELEVIDYS corresponded with increases on the North Star Ambulatory Assessment (NSAA) at one year in crossover patients, while the study remained blinded – MRI results at two years...
– Preliminary total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for full-year 2024, exceeding full-year guidance by over $100 million – Preliminary ELEVIDYS net...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date”) that were previously approved...
– Sarepta anticipates filing for accelerated approval of SRP-9003 in 2025 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.58 | -2.23318618541 | 115.53 | 120.05 | 111.48 | 699844 | 115.22931079 | CS |
| 4 | -11.8 | -9.45891783567 | 124.75 | 128.75 | 111.48 | 896417 | 117.27211097 | CS |
| 12 | 0.47 | 0.417852062589 | 112.48 | 138.81 | 102.155 | 920672 | 120.39006561 | CS |
| 26 | -27.84 | -19.7741316855 | 140.79 | 145 | 102.155 | 930586 | 124.70085741 | CS |
| 52 | -13.12 | -10.4069167923 | 126.07 | 173.1 | 102.155 | 1148946 | 131.03110367 | CS |
| 156 | 39.84 | 54.4932293804 | 73.11 | 173.1 | 55.25 | 1162834 | 115.88772569 | CS |
| 260 | -9.14 | -7.48628061266 | 122.09 | 181.83 | 55.25 | 1117062 | 110.607616 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
